CD274 and melanoma: Outcomes for patients with melanoma have improved over the past decade because of the clinical development and Food and Drug Administration (FDA) approval of immunotherapies targeting checkpoint receptors such as programmed death-1 (PD-1), programmed death ligand 1 (PD-L1) or cytotoxic T lymphocyte antigen-4 (CTLA-4).